←Back to Expert Scholars
Translational Medicine / 转化医学Cancer Peptide Drug Conjugate
Yoav Mor
PhD
🏢BioLineRx🌐Israel
Senior Vice President of Research
25
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Yoav Mor has led development of motixafortide, a CXCR4-targeting peptide used for stem cell mobilization and being evaluated in pancreatic cancer combinations. His work at BioLineRx advances peptide-based cancer therapies. He contributes to peptide drug development in Israel.
Share:
🧪Research Fields 研究领域
CXCR4 antagonist peptides
motixafortide
stem cell mobilization
cancer peptide therapy
tumor microenvironment
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Yoav Mor 的研究动态
Follow Yoav Mor's research updates
留下邮箱，当我们发布与 Yoav Mor（BioLineRx）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment